GlycoT Therapeutics

News

On July 27, 2017, GlycoT was awarded a Phase I SBIR grant (1R43GM123823-01A1) from the National Institute of General Medical Sciences (NIGMS) to establish a robust and scalable process for production of hypersialylated glycoforms of intravenous immunoglobulin (IVIG) with markedly enhanced anti-inflammatory activity.

On March 20, 2018, GlycoT was awarded a Phase I SBIR grant (1R43GM128547-01) from NIGMS to develop a 13C-labeled IgG-Fc glycopeptide library using our technology platform, which could be applied as standards for absolute quantification of antibody glycosylation from recombinant antibodies and clinical samples for quality control of biologics manufacturing, and/or for diagnosis and biomarker discovery.

On April 3, 2019, based on the successful accomplishment of all milestones setup in Phase I SBIR grant, GlycoT was awarded a Phase II SBIR grant (2R44GM123823-01A1) from the NIGMS to continue and expand the R&D work to establish a robust and scalable process for production of hypersialylated glycoforms of intravenous immunoglobulin (IVIG) with markedly enhanced anti-inflammatory activity.